Calculator for ovarian carcinoma subtype prediction.

Mod Pathol 2011 Apr 3;24(4):512-21. Epub 2010 Dec 3.

Genetic Pathology Evaluation Centre, Vancouver, BC, Canada.

With the emerging evidence that the five major ovarian carcinoma subtypes (high-grade serous, clear cell, endometrioid, mucinous, and low-grade serous) are distinct disease entities, management of ovarian carcinoma will become subtype specific in the future. In an effort to improve diagnostic accuracy, we set out to determine if an immunohistochemical panel of molecular markers could reproduce consensus subtype assignment. Immunohistochemical expression of 22 biomarkers were examined on tissue microarrays constructed from 322 archival ovarian carcinoma samples from the British Columbia Cancer Agency archives, for the period between 1984 and 2000, and an independent set of 242 cases of ovarian carcinoma from the Gynaecologic Tissue Bank at Vancouver General Hospital from 2001 to 2008. Nominal logistic regression was used to produce a subtype prediction model for each of these sets of cases. These models were then cross-validated against the other cohort, and then both models were further validated in an independent cohort of 81 ovarian carcinoma samples from five different centers. Starting with data for 22 markers, full model fit, backwards, nominal logistic regression identified the same nine markers (CDKN2A, DKK1, HNF1B, MDM2, PGR, TFF3, TP53, VIM, WT1) as being most predictive of ovarian carcinoma subtype in both the archival and tumor bank cohorts. These models were able to predict subtype in the respective cohort in which they were developed with a high degree of sensitivity and specificity (κ statistics of 0.88±0.02 and 0.86±0.04, respectively). When the models were cross-validated (ie using the model developed in one case series to predict subtype in the other series), the prediction equation's performances were reduced (κ statistics of 0.70±0.04 and 0.61±0.04, respectively) due to differences in frequency of expression of some biomarkers in the two case series. Both models were then validated on the independent series of 81 cases, with very good to excellent ability to predict subtype (κ=0.85±0.06 and 0.78±0.07, respectively). A nine-marker immunohistochemical maker panel can be used to objectively support classification into one of the five major subtypes of ovarian carcinoma.

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2010.215DOI Listing
April 2011
41 Reads

Publication Analysis

Top Keywords

ovarian carcinoma
32
predict subtype
12
models cross-validated
8
carcinoma
8
nominal logistic
8
logistic regression
8
carcinoma samples
8
validated independent
8
models validated
8
carcinoma subtype
8
subtype
8
expression biomarkers
8
case series
8
subtype prediction
8
ovarian
7
models
5
backwards nominal
4
data markers
4
markers full
4
fit backwards
4

Altmetric Statistics

References

(Supplied by CrossRef)

A Jemal et al.
CA Cancer J Clin 2009

J Chan et al.
Br J Cancer 2008

CB Gilks et al.
Hum Pathol 2008

M Köbel et al.
Am J Surg Pathol 2010

RJ Kurman et al.
Am J Surg Pathol 2010

M Köbel et al.
Int J Gynecol Pathol 2010

CB Gilks et al.
Hum Pathol 2009

M Köbel et al.
PLoS Med 2008

V Hess et al.
J Clin Oncol 2004

T Sugiyama et al.
Cancer 2000

DM Gershenson et al.
Cancer 2010

Similar Publications